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Aims: To compare the efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with insulin glargine 100 U/ml (Gla-100) over 12months of
treatment in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs (OADs).
Methods: EDITION 2 (NCT01499095) was a randomized, 6-month, multicentre, open-label, two-arm, phase IIIa study investigating once-daily Gla-300
versus Gla-100, plus OADs (excluding sulphonylureas), with a 6-month safety extension.
Results: Similar numbers of participants in each group completed 12months of treatment [Gla-300, 315 participants (78%); Gla-100, 314 participants
(77%)]. The reduction in glycated haemoglobin was maintained for 12months with both treatments: least squares (LS) mean (standard error) change from
baseline−0.55 (0.06)% for Gla-300 and−0.50 (0.06)% for Gla-100; LS mean difference−0.06 [95% confidence interval (CI)−0.22 to 0.10)%]. A significant
relative reduction of 37% in the annualized rate of nocturnal confirmed [≤3.9mmol/l (≤70mg/dl)] or severe hypoglycaemia was observed with Gla-300
compared with Gla-100: rate ratio 0.63 [(95% CI 0.42–0.96); p= 0.031], and fewer participants experienced≥1 event [relative risk 0.84 (95% CI 0.71–0.99)].
Severe hypoglycaemia was infrequent. Weight gain was significantly lower with Gla-300 than Gla-100 [LS mean difference−0.7 (95% CI−1.3 to−0.2) kg;
p= 0.009]. Both treatments were well tolerated with a similar pattern of adverse events (incidence of 69 and 60% in the Gla-300 and Gla-100 groups).
Conclusions: In people with type 2 diabetes treated with Gla-300 or Gla-100, and non-sulphonylurea OADs, glycaemic control was sustained over
12months, with less nocturnal hypoglycaemia in the Gla-300 group.
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Introduction
New insulin glargine 300U/ml (Gla-300) has a more constant
and prolonged pharmacokinetic (PK) and pharmaco-
dynamic (PD) profile compared with insulin glargine
100U/ml (Gla-100) [1]. The longer duration of action of
Gla-300 could provide effective 24-h glycaemic control with
once-daily dosing, while allowing flexibility in injection time.
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In addition, the more even PK/PD profile may reduce the risk
of hypoglycaemia, a key barrier to initiation and intensification
of insulin therapy [2].
To investigate treatment outcomes with Gla-300, a pro-
gramme of clinical studies (the EDITION programme) was
conducted in people with type 1 or type 2 diabetes. Similar gly-
caemic control, recorded as change in glycated haemoglobin
(HbA1c), with a lower risk of hypoglycaemia, was observed
withGla-300 comparedwithGla-100 during themain 6-month
treatment periods of the EDITION 1, 2 and 3 studies, con-
ducted in people with type 2 diabetes [3–5]. During the main
6-month treatment period of EDITION 2 (NCT01499095),
which enrolled people with type 2 diabetes who were using
basal insulin and oral antihyperglycaemic drugs (OADs), the
relative risk of nocturnal confirmed [≤3.9mmol/l (≤70mg/dl)]
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or severe hypoglycaemia was 29% lower withGla-300 thanwith
Gla-100 [3]. Similarly, fewer participants experienced one or
more confirmed or severe hypoglycaemic event at any time
(24 h) with Gla-300 than with Gla-100. The annualized rates
of confirmed or severe hypoglycaemic events were also lower
with Gla-300 than with Gla-100.Weight gain was low, with sta-
tistically (p= 0.015) lower weight gain observed with Gla-300
compared with Gla-100 at 6months.
After the main 6-month treatment period, participants in
EDITION 2 continued in a 6-month safety extension to exam-
ine the longer-termoutcomes of treatmentwithGla-300 in peo-
ple with type 2 diabetes using basal insulin and OADs. The
12-month results of the EDITION 2 study are reported in the
present paper.
Participants and Methods
Study Design and Participants
EDITION 2 (NCT01499095) was a multicentre, multinational,
randomized, open-label, two-arm, parallel-group, phase IIIa
study conducted between 14 December 2011 and 26 April
2013 in 13 countries (two in North America, eight Euro-
pean countries and Chile, Mexico and South Africa). The
protocol and study design have been described previously
[3]. Adults (aged ≥18 years old) with type 2 diabetes treated
with ≥42U/day basal insulin (Gla-100 or NPH insulin) and
OADs (except sulphonylureas) were randomized 1 : 1 to receive
Gla-300 or Gla-100 for 6months, with a 6-month safety exten-
sion period [3]. Exclusion criteria included: HbA1c <7.0 or
>10%; recent (within the past 3months) use of premixed
insulin, insulin detemir or initiation of new glucose-lowering
agents; recent (within the past 2months) use of sulphony-
lurea; recent (>10 days in the past 3months) use of human
regular insulin or mealtime insulin; and rapidly progress-
ing diabetic retinopathy, end-stage renal disease (defined as
requiring dialysis or transplantation [6]), or clinically sig-
nificant cardiac, hepatic or other systemic disease. Gla-300
(using a modified SoloSTAR® pen, sanofi-aventis U.S. L.L.C.,
Bridgewater, NJ, USA) or Gla-100 (using a SoloSTAR® pen)
was self-administered once daily at the same time each day
in the evening, defined as the time immediately before the
evening meal until bedtime. The insulin dose was to be titrated
based on fasting self-monitored plasma glucose (SMPG) val-
ues, according to a prespecified titration algorithm, seeking an
SMPG target of 4.4–5.6mmol/l (80–100mg/dl). Irrespective of
treatment allocation, rescue treatmentwith a new antihypergly-
caemic drug was allowed if the fasting plasma glucose (FPG) or
HbA1c levels were above target values and there was no reason-
able explanation for insufficient glucose control, or if appropri-
ate action failed to decrease the levels to below threshold values.
The choice of rescue therapy (rapid insulin or other antihyper-
glycaemicmedications) was based on the investigator’s decision
and local approved guidelines.
The protocol was approved by local or national ethics
committees, and the study was conducted according to
Good Clinical Practice and the Declaration of Helsinki. All
participants provided written informed consent.
Efficacy and Safety Analyses
Efficacy analyses included change in HbA1c, FPG, SMPG
and daily basal insulin dose from baseline to the end of
12months’ treatment. Hypoglycaemic events were recorded
using American Diabetes Association definitions [7]. Severe
hypoglycaemia and hypoglycaemia confirmed by an SMPG
reading [symptomatic or asymptomatic, confirmed using a
plasma glucose threshold of ≤3.9mmol/l (≤70mg/dl)] were
reported in a composite category of confirmed or severe
hypoglycaemia. A more stringent plasma glucose threshold of
<3.0mmol/l (<54mg/dl) was also used. Severe hypoglycaemia
was defined as an event requiring the assistance of another
person to administer carbohydrate or glucagon or take resusci-
tative actions. Each category of hypoglycaemia was analysed as
the percentage of participants reporting at least one event and as
events per participant-year (annualized rate). Hypoglycaemic
events were analysed by occurrence at any time (24 h) and dur-
ing the night (nocturnal; 00:00–05:59 hours). Change in body
weight was assessed as a safety outcome. Adverse events (AEs),
including injection site and hypersensitivity reactions, were
recorded during the whole study period. Standard safety labo-
ratory assessments for anti-insulin antibodies (status, titre and
cross-reactivity with human insulin) were performed.The Dia-
betes Treatment SatisfactionQuestionnaire status (DTSQs) was
used to assess participant satisfaction with current treatment,
including Perceived Frequency of Hyperglycaemia (item 2
of the DTSQs) and Perceived Frequency of Hypoglycaemia
(item 3 of the DTSQs) [8,9].
Data Analysis and Statistics
The modified intention-to-treat (mITT) population was
defined as all randomized participants who received at least
one dose of study insulin and had both a baseline and at least
one post-baseline primary or secondary efficacy endpoint
assessment. Analyses of glycaemic control used the mITT
population. A mixed-effects model for repeated measures,
conducted on rescue-free measurements, was used to analyse
HbA1c and FPG. Descriptive analyses were performed on dose
and eight-point SMPG.
Safety analyses included all participants randomized and
exposed to at least one dose of study insulin. Hypoglycaemic
event rates were analysed using an overdispersed Poisson
regression model. Body weight and insulin dose were analysed
using an analysis of covariance model. AEs were coded using
the Medical Dictionary for Regulatory Activities (MedDRA)
system.
Results
Study Population
Of the 811 randomized participants, 404 were assigned to
Gla-300 and 407 to Gla-100. In each group, 1 participant was
randomized but not treated, and a further participant in the
Gla-100 group was randomized but did not have a baseline or
post-baseline primary or secondary efficacy endpointmeasure-
ment. These participants were excluded from the mITT popu-
lation (Figure 1). A total of 315/404 (78%) and 314/407 (77%)
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315 (78.0%)
Received rescue therapy 19
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Poor adherence 4
Lack of efficacy 0
Other 30
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Figure 1. Study flow. *One participant in each group received rescue therapy and withdrew from the study. The upper portion with open boxes shows
participant flow during the main 6-month study period; the lower portion with shaded boxes shows flow during the extension phase up to month 12.
Gla-100, insulin glargine 100U/ml; Gla-300, insulin glargine 300U/ml; mITT, modified intention-to-treat.
participants in the Gla-300 and Gla-100 groups, respectively,
completed 12months of treatment (Figure 1).
Baseline characteristics have been reported previously
and were similar in the Gla-300 and Gla-100 groups [3].
Participants had a mean [standard deviation (s.d.)] age of
58 (9.2) years, a mean (s.d.) body mass index (BMI) of 35
(6.4) kg/m2 and a mean (s.d.) duration of diabetes of 12.6
(7.0) years. Their mean (s.d.) HbA1c concentration was
8.24 (0.82)% [66.5 (9.0)mmol/mol], FPG concentration 8.0
(2.8)mmol/l [144.7 (51.0)mg/dl] and basal insulin dosage 0.67
(0.24)U/kg/day.
Almost all participants used biguanides in the Gla-300 and
Gla-100 groups, both before the start of treatment [389/404
participants (96.3%) and 383/407 participants (94.1%), respec-
tively] and during the on-treatment period [385/404 partici-
pants (95.3%) and 381/407 participants (93.6%), respectively].
Dipeptidyl peptidase-4 inhibitors were used before treatment
and during the treatment period by 33 participants (8.2%) and
34 participants (8.4%), respectively, in the Gla-300 group, and
by 51 participants (12.5%) and 54 participants (13.3%), respec-
tively, in the Gla-100 group. Sulphonylureas had been used in
the 3months before randomization by 32 (3.9%) of all random-
ized participants. Overall, 16 (2.0%) participants used sulpho-
nylureas during the study, including use as rescue therapy by
2 participants in the Gla-300 group and 1 participant in the
Gla-100 group. During the 12-month on-treatment period, 33
participants (8.2%) in the Gla-300 group and 41 (10.1%) in the
Gla-100 group received rescue therapy; relative risk 0.81 [95%
confidence interval (CI) 0.52–1.25; Figure 1], most commonly
as rapid-acting insulin.
Insulin Dose and Glycaemic Control (mITT Population)
Over the whole 12-month study period, the mean basal insulin
dosage increased in both groups, primarily during the first
12weeks and to a greater extent in the Gla-300 group than
the Gla-100 group (Figure 2A). The mean basal insulin dosage
continued to increase gradually up to month 12 in both treat-
ment groups, reaching 0.97U/kg/day in the Gla-300 group and
0.87U/kg/day in the Gla-100 group [mean (standard error) dif-
ference 0.11 (0.02)U/kg/day; p< 0.0001].
The mean HbA1c decreased from baseline to month 12 to
a similar extent in each of the two treatment groups, with the
greatest decrease occurring between baseline and week 12 in
both groups (Figure S1A). The mean (s.d.) HbA1c at month 12
was 7.62 (1.03)% [59.8 (11.3)mmol/mol] in the Gla-300 group
and 7.64 (1.21)% [60.0 (13.2)mmol/mol] in the Gla-100 group
(Figure 2B). The least squares (LS) mean difference in change
from baseline to month 12 between groups was −0.06 (95% CI
−0.22 to 0.10)% [−0.66 (95% CI −2.4 to 1.1)mmol/mol].
In addition, FPG decreased to a similar extent in the two
treatment groups, primarily during the initial 12weeks of treat-
ment, remaining relatively stable during the remainder of the
12-month study period (Figure S1B). The LS mean difference
in FPG change from baseline to month 12 between the groups
was 0.18 (95% CI −0.21 to 0.57)mmol/l [3.3 (95% CI −3.7 to
10.3)mg/dl].
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Figure 2. (A) Mean daily basal insulin dose (B) glycated haemoglobin
(HbA1c)± standard error by visit (modified intention-to-treat population).
Gla-100, insulin glargine 100U/ml; Gla-300, insulin glargine 300U/ml; s.e.,
standard error.
The mean eight-point SMPG profiles decreased from base-
line to month 12 in both treatment groups at all time points. At
month 12, mean plasma glucose levels were similar in the two
treatment groups from 03:00 hours to post-lunch, but numeri-
cally lower in theGla-300 group than in theGla-100 group from
pre-dinner to bedtime (Figure S1C).
Hypoglycaemia (Safety Population)
Nocturnal Hypoglycaemia. The cumulative mean number
of nocturnal (00:00–05:59 hours) confirmed [≤3.9mmol/l
(≤70mg/dl)] or severe hypoglycaemic events per participant
is reported in Figure 3A. There was a significant 37% relative
reduction in annualized rate with Gla-300 compared with
Gla-100 [1.74 vs 2.77, rate ratio 0.63 (95% CI 0.42–0.96);
p= 0.0308; Figure 3B], and a 16% relative risk reduction in
the percentage of participants experiencing ≥1 nocturnal con-
firmed or severe hypoglycaemic event during the 12-month
study period [38% vs 45%, relative risk 0.84 (95%CI 0.71–0.99);
Table S1].
Considering all hypoglycaemia, there were fewer nocturnal
hypoglycaemic events reported with Gla-300 (668 events or 1.8
events per participant-year) versus Gla-100 [1110 events or 2.9
events per participant-year; rate ratio 0.61 (95% CI 0.41–0.92);
Table S1]. A total of 160 participants (40%) in theGla-300 group
and 187 participants (46%) in the Gla-100 group experienced
at least one nocturnal hypoglycaemic event [relative risk 0.86
(95% CI 0.73–1.01)]. Annualized event rates and percentages
of participants experiencing at least one event for these and
other categories of hypoglycaemia during the night are shown
in Table S1.
Hypoglycaemia at Any Time. The cumulative mean number of
confirmed or severe hypoglycaemic events per participant at
any time (24 h) is reported in Figure 3C. The annualized event
rate (Figure 3D) and the percentage of participants with at
least one event during 12months of treatment were numeri-
cally lower but not significantly different with Gla-300 com-
pared with Gla-100. Annualized rates of confirmed or severe
hypoglycemia were 11.6 for Gla-300 and 13.2 for Gla-100, and
the corresponding percentages of participants with at least one
event were 78% for Gla-300 and 82% for Gla-100 (Table S1).
Over the 24-h period, the percentage of participants report-
ing confirmed or severe hypoglycaemia tended to be lower in
theGla-300 group than in theGla-100 group between 00:00 and
14:00 hours, andwas similar in the two groups from14:00 hours
until midnight (Figure 4).
Other categories of hypoglycaemia, expressed as annualized
event rates and percentages of participants experiencing at least
one event at any time (24 h) are shown in Table S1.
Severe Hypoglycaemia. During the 12-month study period,
severe hypoglycaemia at any time (24 h) was reported by 7
(1.7%) participants (10 events) in the Gla-300 group and 6
(1.5%) participants (13 events) in the Gla-100 group, corre-
sponding to a rate of 0.03 events per participant-year in both
treatment groups (Table S1).Three participants reported severe
nocturnal hypoglycaemic events [1 participant (0.2%) using
Gla-300 and 2 participants (0.5%) using Gla-100].
Body Weight
The significant between-group weight difference observed at
6months wasmaintained at 12months of treatment (Figure S2)
[3]. The mean (s.d.) change in body weight, based on the last
on-treatment value, was significantly lower with Gla-300 than
with Gla-100 [0.4 (4.1) vs 1.2 (3.6) kg]; the LS mean difference
between groups atmonth 12was−0.7 (95%CI−1.3 to−0.2) kg;
p= 0.009.
Treatment Satisfaction
Participants in both treatment groups reported high satisfac-
tion throughout the study; DTSQs treatment satisfaction scores
were similar in each group. The improvement in DTSQs scores
observed at month 6 was maintained at month 12, resulting in
an overall mean (s.d.) increase from baseline to month 12 of
4.3 (6.6) with Gla-300 and 4.4 (7.5) with Gla-100. Perceived fre-
quency of hypoglycaemia remained stablewith either treatment
[mean (s.d.) change from baseline to month 12, 0.05 (1.86) in
both treatment groups]. Perceived frequency of hyperglycaemia
slightly decreased in both treatment groups [mean (s.d.) change
from baseline to month 12, −1.38 (2.18) and −1.37 (2.29) for
Gla-300 and Gla-100, respectively].
Adverse Events
There was a similar pattern of treatment-emergent AEs
(TEAEs) in each treatment group, with incidences of 69 and
60% in the Gla-300 and Gla-100 groups (Table 1). Fourteen
(3.5%) TEAEs in the Gla-300 group and 15 (3.7%) in the
Gla-100 group were considered by the study investigator to
be related to study medication. The most commonly reported
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Table 1. Adverse events (safety population).
n (%)
Gla-300
(n= 403)
Gla-100
(n= 406)
Participants with any TEAE 278 (69.0) 244 (60.1)
Participants with any treatment-emergent SAE 30 (7.4) 30 (7.4)
Participants with any TEAE leading to death 4 (1.0) 2 (0.5)
Participants with TEAE leading to permanent
treatment discontinuation
11 (2.7) 7 (1.7)
Any injection site reaction 5 (1.2) 12 (3.0)
Any hypersensitivity reaction 19 (4.7) 20 (4.9)
TEAE, treatment-emergent adverse event; SAE, serious adverse event.
TEAE was nasopharyngitis (Gla-300, 12.2%; Gla-100, 7.6%).
Injection site reactions were experienced by 5 (1.2%) partici-
pants in the Gla-300 group and 12 (3.0%) participants in the
Gla-100 group. Hypersensitivity reactions were reported by 19
participants (4.7%) in the Gla-300 group and 20 participants
(4.9%) in the Gla-100 group.
The percentage of participants with treatment-emergent
serious AEs (SAEs) or TEAEs leading to treatment discontin-
uation during the 12-month on-treatment period were similar
in the Gla-300 and Gla-100 groups (Table 1). Two (0.5%) SAEs
in the Gla-300 group (one case of hypoglycaemia and one acute
myocardial infarction) and one (0.2%) in the Gla-100 group
(hypoglycaemia) were considered possibly related to study
medication.
Four participants (1.0%) in the Gla-300 group and 2 par-
ticipants (0.5%) in the Gla-100 group died owing to a TEAE.
All those who died had pre-existing, significant-event-related
pathology and/or had multiple risk factors contributing to the
fatal outcome. In the Gla-300 group, three deaths (one from
myocardial infarction, one frommetastatic adenocarcinoma of
the oesophagus and one from coronary artery disease) were not
considered treatment-related, and one death (attributable to
acutemyocardial infarction) was considered by the study inves-
tigator as possibly related to study medication or non-study
medication (specifically metformin). The two deaths in the
Gla-100 group (one myocardial infarction and one infection)
were not considered related to study medication.
No differences were found between treatment groups
in safety laboratory measurements, physical examination,
vital signs or ECGs, or in numbers of participants report-
ing anti-insulin antibodies, anti-insulin antibodies titre or
cross-reactivity to human insulin.
Discussion
These 12-month treatment results confirm the findings of the
6-month initial study period [3]. Equivalent glycaemic control
was attained with both insulins, but less nocturnal confirmed
[≤3.9mmol/l (≤70mg/dl)] or severe hypoglycaemia and less
weight gain was observed with Gla-300. The safety profiles of
Gla-300 and Gla-100 were similar.
The reduction in HbA1c values observed in both treat-
ment groups from baseline to month 6 [3] was maintained at
12months. When examining the mean eight-point SMPG pro-
files, blood glucose was lower with Gla-300 than with Gla-100
between the pre-dinner and bedtime time points. Better gly-
caemic control with Gla-300 than with Gla-100 at the end of a
once-daily evening dosing schedule might be explained by the
longer duration of action of Gla-300, which has been shown in
PK/PD studies [1].
In addition to providing sustained glycaemic control, there
was a 37% relative reduction in the annualized rate of noc-
turnal confirmed [≤3.9mmol/l (70mg/dl)] or severe hypogly-
caemic events with Gla-300 compared with Gla-100, and a
consistently lower proportion of participants experiencing at
least one event. While it is necessary to use defined nocturnal
and diurnal intervals of time for the purpose of analysis, these
arbitrary definitions may not correspond to the daily habits of
participants with regard to timing of sleep and the first meal of
the day. As well as providing a significant reduction in hypogly-
caemia during the predefined nocturnal (00:00–05:59 hours)
period, a lower rate of hypoglycaemia compared with Gla-100
was observed with Gla-300 until the middle of the next day, in
line with its PK/PD profile. In future studies and analyses, the
actual timing of the overnight fasting interval should be consid-
ered when assessing the risk of hypoglycaemia. Severe hypogly-
caemic events were uncommon in both treatment groups.
Lower nocturnal hypoglycaemia, with a small but signifi-
cant improvement in HbA1c, was seen with Gla-300 compared
with Gla-100 after 12months of treatment in the EDITION 1
study, in which people with type 2 diabetes were treated with
basal plus mealtime insulin [5]. Similar glycaemic control
with reduced nocturnal hypoglycaemia has been observed with
insulin degludec 100U/ml compared with Gla-100 in people
with type 2 diabetes treated with basal plus mealtime insulin
[10], and in insulin-naïve people [11]. By contrast, another
study in insulin-naïve people with type 2 diabetes, using amore
concentrated 200U/ml formulation of insulin degludec, did not
show a difference in nocturnal hypoglycaemia compared with
Gla-100 [12]; however, differences in study populations and
definitions of hypoglycaemia limit direct comparisons of hypo-
glycaemia rates across all of these studies.
The mean daily doses of Gla-300 and Gla-100 remained
relatively consistent throughout the 6-month extension period
of this study. A higher mean daily insulin dose of Gla-300 was
required, with the majority of dose titration occurring during
the first 12weeks of the study, as reported previously [3].
The cause of the difference in insulin dose is uncertain, but
it may be attributable to greater inactivation of the glargine
molecule by tissue proteases as a consequence of the longer
residence time of Gla-300 in the subcutaneous depot. A longer
residence time is consistent with the extended absorption of
Gla-300, which results in the more prolonged PK/PD profile
of action observed with Gla-300 compared with Gla-100
[1,13,14].
Weight gain after 12months of treatment remained low in
both groups and was not felt to be of clinical concern. Fur-
thermore, there was slightly, but statistically significantly, less
weight gain with Gla-300 than with Gla-100. This was already
apparent after 6months [3]. A trend for lower weight gain with
Gla-300 compared with Gla-100 has also been observed in
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EDITION studies in other populations [4,15–17]. Further anal-
yses are warranted to determine whether this difference can be
explained by the difference in hypoglycaemia or other factors.
Occurrence of TEAEs, treatment discontinuation, injection
site reactions and hypersensitivity reactions occurred with a
similar pattern with Gla-300 and Gla-100. Both treatments
were well tolerated and no safety concerns were identified at
12months; longer-term observation will be required to con-
tinue to monitor the safety profile of Gla-300.
Limitations of the present study include its open-label nature
and a necessary reduction in ascertainment of hypoglycaemia
and other events during the extension phase. The EDITION 2
study was restricted to the investigation of clinical outcomes
of Gla-300 treatment versus Gla-100 in participants using a
basal insulin and OAD (excluding sulphonylurea) regimen;
however, the EDITION programme of clinical studies is inves-
tigating outcomes of Gla-300 vs Gla-100 treatment in other
populations using different treatment regimens to cover the
broader cross-section of people with diabetes. Analyses of the
6-month extension phases of EDITION 3 (insulin-naïve partic-
ipants), EDITION 4 (people with type 1 diabetes), EDITION
JP 1 (Japanese people with type 1 diabetes) and EDITION JP 2
(Japanese people with type 2 diabetes using basal insulin plus
OADs) are ongoing.
In summary, in a population using basal insulin plus
OADs, excluding sulphonylurea, with a long duration of type
2 diabetes, high BMI, long-term previous insulin use and
high baseline HbA1c, findings from 12months’ treatment
with Gla-300 support and extend the EDITION 2 6-month
results. The sustained glycaemic control achieved in this
challenging-to-treat population along with less nocturnal
hypoglycaemia and weight gain compared with Gla-100 is
reassuring and suggests that these favourable results may be
applicable to long-term treatment in clinical practice.
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